CD34 and neoplasm: This approach enables the study of a patient’s immune response with matched immune-tumor cell donors shortly after TIL or peripheral blood mononuclear cells (PBMC) injection, avoiding the long reconstitution time after CD34+ hematopoietic progenitor cell injection.